Objective: Maternal plasma cell-free DNA (cfDNA) analysis is a powerful screening tool for Down syndrome. In a pilot series, we examined biologic causes of discordance between the cfDNA test results and the fetal karyotype. We also explored the feasibility of obtaining trio biospecimens by using parental engagement.
| INTRODUCTION

Since its incorporation into clinical care in the United States in
October 2011, massively parallel sequencing of circulating cell-free (cf) DNA in maternal plasma-noninvasive prenatal testing-has revolutionized prenatal screening and diagnosis for fetal aneuploidy. It is the largest and fastest growing assay in genomic medicine, and up to 6 million tests have been performed globally to date. 1 Compared with serum screening, cfDNA has better sensitivities, specificities, positive and negative predictive values, and significantly lower false-positive rates. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] Multiple professional societies, such as the American College of Obstetricians and Gynecologists, the Society for Maternal Fetal Medicine, the International Society for Prenatal Diagnosis, and the American College of Medical Genetics and Genomics, have endorsed offering cfDNA after pretest counseling to women at high risk for having a fetus with a chromosome aneuploidy. [16] [17] [18] [19] With improved screening performance for the common autosomal aneuploidies, there has been up to a 79% decrease in diagnostic procedures such as amniocentesis and chorionic villus sampling (CVS) performed in the United States, [20] [21] [22] with an associated decrease in procedure-related miscarriages. Large-scale clinical studies in general obstetrical populations have demonstrated that cfDNA performs better than both serum biochemistry and the first trimester combined test, with significantly higher positive predictive values and lower false-positive rates. 11, 13, 15, 23 Some societies, notably American College of Obstetricians and Gynecologists/Society for Maternal Fetal Medicine and American College of Medical Genetics and Genomics, indicate that if low-risk women request cfDNA analysis after pretest counseling, this is acceptable. 16, 19 This has led to increased use of cfDNA as a firsttier screen.
As clinical use of cfDNA with the current whole chromosome aneuploidy panels has expanded, up to 10% of pregnant women have there is a tumor that is shedding DNA fragments into the maternal plasma that could be detected with appropriate evaluation. [26] [27] [28] [29] There is also the possibility that due to limited understanding of the underlying biology and the potential causes of false-positive results, chromosomally normal fetuses will be unnecessarily terminated. One study showed that 6% of women terminated their pregnancies for a positive cfDNA result, without obtaining a diagnostic fetal karyotype. 25 In addition, determining the relative frequencies and consequences of confined placental mosaicism (CPM) may allow identification of fetuses at risk for prenatal growth restriction.
30-32
In current clinical practice, 3 different technical approaches are used for sequencing cfDNA: massively parallel sequencing of the whole genome, targeted sequencing, and single nucleotide polymorphism detection. 25, 33 All methods similarly sequence the total cfDNA fragments isolated from the maternal plasma and then create numerous tags for comparison of the sequenced DNA to either reference chromosomes or parental genomes. Tag excess or deficiency implies aneuploidy for all or part of a chromosome. Chromosome counts derive from both maternal and feto-placental DNA fragments. As such, any significant deviation from the reference values could be maternal or placental in origin. An increasing body of literature has documented many potential biological reasons for discordance between cfDNA results and the fetal karyotype. 24, [34] [35] [36] [37] [38] [39] [40] Because the circulating fetal cfDNA mainly derives from the placenta, 41 there is the possibility that a chromosome abnormality is in the placenta (or part of it) but is not present in the fetus. This is known as CPM; the CVS literature has documented CPM in 1 to 2% of first trimester placentas.
42,43
Another major reason for a discordant cfDNA result is that the pregnant woman herself 44 has a partial or mosaic autosomal 45 Here, we hypothesized that by collecting additional clinical information and relevant biomaterials, we would be able to determine a biological explanation for the discordant results between the cfDNA in maternal blood and the diagnostic fetal karyotype. We also wished to test whether droplet digital PCR (ddPCR) would be a cost-effective method of analyzing multiple biospecimens in each individual case. We also examined the effectiveness of active participant involvement, by sending relevant biospecimen collection kits to the pregnant woman herself.
| MATERIALS AND METHODS
The Institutional Review Boards of Tufts Medical Center (Tufts MC),
Brigham and Women's Hospital, and the Jackson Laboratory for Genomic Medicine reviewed and approved the study protocol.
| Study participants
The inclusion criteria were pregnant women with a cfDNA screening result discordant from a diagnostic fetal karyotype obtained by an amniocentesis or CVS. The discordant results could include both autosomal and sex chromosomal and include single or multiple aneuploidies. For this pilot study, we also included cases in which an ultrasound examination was discordant with cfDNA results (e.g., female genitalia on ultrasound examination and Y chromosome detected on cfDNA). The placenta had to be available for biopsies.
The exclusion criteria were (1) women who were not pregnant, (2) women whose cfDNA results were concordant with their diagnostic tests, or (3) women without a diagnostic test to confirm the abnormal cfDNA results. The pilot study used a convenience sample. What does this study add?
• Presumed biologic etiologies for discordant cfDNA can be identified in over half of the cases by an in-depth review of clinical records and/or multispecimen genomic examination. Patients and providers are motivated to participate and will be instrumental in expanding assessments to a larger, more diverse obstetric population.
explained the study in person or over the telephone and sent an electronic version of the consent form for signature. Once the signed consent form was received, the subject was formally enrolled in the study ( Figure 1 ).
To test the feasibility of successful collection of placental biopsies at delivery in locations across North America, we developed and refined a set of instructions for the participant. Using an express courier (FedEx), after consent was received, we sent each participant a kit containing venipuncture collection tubes, sterile biopsy forceps and scissors, and tubes with sterile culture medium. The kit contained instructions for the provider regarding sample procurement, a short data sheet, and the ability to return the kit in the same mailer with a prepaid label. The kit was sent to the home addresses of the pregnant participants who were asked to bring it to the hospital when they were admitted for delivery. Because we were unable to predict which physician would be present at the delivery, we sent the kit directly to the participants who had a vested interest in obtaining the study results.
Refinements to instructions occurred during the pilot study to facilitate collection of all blood samples and the appropriate timing for sample return to the testing laboratory.
| Genomic DNA isolation
Maternal antepartum and postpartum peripheral blood samples All DNA samples were stored at −20°C until being used for ddPCR experiments.
| Detection of copy number variation by using droplet digital PCR
The QX200 ddPCR System (Bio-Rad Laboratories) was used for detection of copy number (CN) of chromosomes 13, 18, 21, X, and Y in this study. All the ddPCR assay probes were ordered through Bio-Rad Laboratories (Hercules, CA In 12 of the 13 remaining cases, the delivering obstetrical staff correctly followed the placental biopsy instructions and mailed the biospecimens back to the laboratory in a timely manner. In the 13th
case, a woman whose specimens were correctly collected ended up bringing her collection box home with her and kept it for 14 days before sending it to the laboratory. Her results were excluded from the analysis.
| Participant clinical data
In 3 of 12 participants, a presumptive explanation for the discordant results was obtained by reviewing additional clinical data from the referring clinical team. Two of the 3 cases involved sex chromosome discordance (cfDNA male with normal fetal 46,XX or female phenotype on ultrasound). In the first case, the woman was the recipient of a kidney transplant from her brother, and in the second case, record review indicated that the pregnancy was conceived by in vitro fertilization.
Ultrasound examination at 5 weeks documented 2 gestational sacs, and at a 7-week ultrasound examination, only a single heart beat was observed, consistent with vanishing twin. In the third case, a woman with known liver masses ultimately shown to be due to metastatic colon cancer had cfDNA results consistent with genome wide alterations and a normal fetal karyotype. This patient has been reported separately. Presumptive explanation
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laboratory, all met quality and quantity assurance standards for analysis by ddPCR (except the case delayed for 2 weeks at home). Three or more placental biopsies were obtained in all cases and blood samples from 12 of 13 women and 11 of 13 of newborns. Two cord blood samples were not collected; 1 was from a case of fetal demise (BWH002; Table 1 ).
| Results from ddPCR studies of biospecimens
Raw ddPCR data for the 12 cases are included in the Appendix.
| Sex chromosomes
Droplet digital PCR results were consistent with the fetal sex (genomic or clinical) in all cases except for 1. This single instance was a stillbirth with cfDNA results positive for monosomy, and with an amniotic fluid karyotype of 45, X [9] /46, XY [11] . The 3 placental biopsy were all consistent with XY. At fetopsy, the phenotypic sex was male.
| Autosomes
Of the 12 cases analyzed by ddPCR, 5 had completely normal (diploid) results with all 3 autosomal sequences. In the remaining 7, 3 had ddPCR results consistent with the cfDNA findings (Table 2A) . These included 2 cases of trisomy 13 and 1 case of 22q11.2 deletion, all due to presumed CPM. Figure 2 is representative of the ddPCR results for CPM of trisomy 13. The case of CPM for 22q11.2 deletion has been reported earlier. 52 In 4 cases, additional CN variants involving chromosomes 13, 21, and X were found that were discordant with the cfDNA test report (Table 2B ).
| DISCUSSION
Using the pilot protocol described in the methods, we showed that we were able to resolve cfDNA/karyotype discordancy for 7 of 12 cases.
These initial data support the premise that a systematic and comprehensive approach is possible and feasible. Among our convenience sample, maternal malignancy and CPM represented mechanisms with clinical significance for subsequent maternal and pregnancy care. 27, 53 This is an argument for the clinical utility of our approach. The need for in depth maternal and antepartum clinical information is highlighted by our cases of discordance likely due to a maternal renal transplant and a vanishing twin.
| Patient engagement and participation
The protocol presented and piloted here has several strengths. The cases were prospectively ascertained. We found that participants and Copy number data are the average of 2 replicates (2 wells) from each assay.
MX, monosomy X; T13, trisomy 13; T18, trisomy 18.
*Underline denotes significant deviation from copy number in controls.
providers were highly motivated to obtain results and willing to play an active role in the process. Detailed instructions, a simplified collection process (providing all needed components within a prepaid return con- Additionally, the delivering obstetrician may be unaware of the potential for biologic causes of cfDNA-fetal discordancy and typically does not pursue placental evaluation for CPM. To address these challenges, systematic clinical data collection from the pregnancy, including adverse events, and a standardized approach to documentation and analysis of the neonate and placenta are needed.
| Collection of biospecimens
Future analysis to understand the biologic causes of cfDNA-fetal discordance and the impact on pregnancy outcomes will require a large 
| ddPCR analysis
Using ddPCR provided cost efficacy and potentially greater sensitivity and specificity. For the noninvasive detection of fetal, single gene disorders using cfDNA, ddPCR is emerging as a highly sensitive and specific modality. 54 Our analyses were mainly targeted to the common aneuploidies (chromosomes 13, 18, 21, or X). One exception was a case of a positive 22q deletion cfDNA report. Cell-free DNA protocols have quickly advanced, and in addition to detection of subchromosome alterations, approaches for assessing rare autosomal trisomies by cffDNA have now emerged. 40 As a convenience population, our data were limited in the identification of these potential contributors. We 
| STUDY LIMITATIONS
Our proposal for a systematic approach has limitations identified during the study. Our approach is dependent upon referrals from providers as well as the participants themselves. This pilot was designed to study false-positive cases, and as such, false-negative cases were not In summary, the results of our pilot study support the premise that a systematic approach to the investigation of discordant cfDNA results is needed and is feasible, even in a complex health care system such as the one that exists in the United States. Only with a multiteam and multispecimen approach can the various biological explanations for cfDNA discordance be assessed and further analyzed.
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A.3 | Screening of chromosomal aneuploidy in samples from patient BWH002 by ddPCR:
The data in Table A3 showed the following: (1) Placenta biopsies 2 and 3 showed increased copy number of chromosome 13 (CN = 2.29) and (2) a male baby 
A.4 | Screening of chromosomal aneuploidy in samples from patient Tufts001 by ddPCR:
The data in Table A4 showed the following: (1) Placenta biopsies 2 and 3 showed significantly increased copy number of chromosomes 13 and 21, respectively, suggesting possible confined placenta mosaicism (CPM) in this patient, and (2) a male baby A.5 | Screening of chromosomal aneuploidy in samples from patient Tufts002 by ddPCR:
The data in Table A5 showed the following: (1) Placenta biopsy 1 showed significantly increased copy number of chromosomes 13, suggesting possible confined placenta mosaicism (CPM) in this patient, and (2) a male baby A.6 | Screening of chromosomal aneuploidy in samples from patient Tufts003 by ddPCR:
The data in Table A6 showed the following: (1) The maternal plasma sample showed significantly increased copy number of chromosome 13, which was not observed in the placenta biopsies and cord blood, suggesting maternal origin, and (2) a female baby Copy number data significantly different from disomy controls are indicated in bold and underline.
A.7 | Screening of chromosomal aneuploidy in samples from patient Tufts005 by ddPCR:
The data in Table A7 showed the following: (1) All the samples examined from this patient had normal copy numbers of chromosomes 13, 18, and 21 and the sex chromosomes and (2) a female baby.
A.8 | Screening of chromosomal aneuploidy in samples from patient Tufts006 by ddPCR:
The data in Table A8 showed the following: (1) All the samples examined from this patient had normal copy numbers of chromosomes 13, 18, and 21 and the sex chromosomes and (2) a female baby A.9 | Screening of chromosomal aneuploidy in samples from patient Tufts007 by ddPCR:
The data in Table A9 showed the following: (1) All the samples examined from this patient had normal copy numbers of chromosomes 13, 18, and 21 and the sex chromosomes and (2) a female baby.
A.10 | Screening of chromosomal aneuploidy in samples from patient Tufts008 by ddPCR:
The data in Table A10 showed the following: (1) All the samples examined from this patient had normal copy numbers of chromosomes 13, 18, and 21 and the sex chromosomes and (2) a female baby A.11 | Screening of chromosomal aneuploidy in samples from patient Tufts009 by ddPCR:
The data in Table A11 showed the following: (1) All the samples examined from this patient showed normal copy numbers of chromosomes 13, 18, and 21 and the sex chromosomes and (2) a male baby A.12 | Screening of chromosomal aneuploidy in samples from patient Tufts011 by ddPCR:
The data in Table A12 showed the following: (1) All the samples examined from this patient showed normal copy numbers of chromosomes 13, 18, and 21 and the sex chromosomes and (2) a female baby A.13 | Screening of chromosomal aneuploidy in samples from patient Tufts012 by ddPCR:
The data in Table A13 showed the following: (1) All the samples examined from this patient showed normal copy numbers of chromosomes 13, 18, and 21 and the sex chromosomes and (2) a female baby 
